The following is a summary of the SIGA Technologies, Inc. (SIGA) Q4 2023 Earnings Call Transcript:

Financial Performance:

• SIGA reported full-year 2023 product revenues of $131 million, showing a 51% increase over 2022, largely attributed to Q4 sales.

• Pretax operating income of $84 million signified a 96% increase over the prior year.

• The company conducted a $43 million capital management scheme through cash dividends and share buybacks.

• The Board of Directors announced a special dividend of $0.60 per share to be disbursed in April, marking a 33% increase over the last special dividend.

Business Progress:

• SIGA's TPOXX gained steady government contracts over the past decade.

• The company completed safety trials for TPOXX's use as post-exposure prophylaxis and anticipates submitting a supplemental New Drug Application within a year.

• Additionally, four trials and observational studies are ongoing for the treatment of monkeypox using TPOXX.

• Plans for geographic expansion and collaborations with global governments are in the works to leverage antiviral expertise and the company targets an RFP for the U.S. Strategic National Stockpile this year.

• SIGA also managed its supply chain challenges to ensure timely deliveries, and is working on normalizing operations for the coming year.

More details: SIGA Technologies IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.